Danaher Corporation vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Danaher Corporation trades at $217.88 (market cap $152.87B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.68 (market cap $311.72M). The key difference: Danaher Corporation is far larger — about 490.4× Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037's market cap, and Danaher Corporation pays a 0.74% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| DHR | USOI | |
|---|---|---|
Market Cap | $152.87B | $311.72M |
Volume | 5,228,698 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $242.05 | $61.17 |
52-Week Low | $161.91 | $42.27 |
Typical Hold Time | 69 Days | 48 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
USOI trades at $44.61, down 0.82% today, with a bearish technical signal driven by moving averages. Support levels are at $44 and $43, while resistance sits at $45 and $46. Financial ratios like P/E and P/S are unavailable in the data, limiting fundamental clarity. Recent portfolio commentary from Seeking Alpha on September 3, 2026, highlighted strategic cash-raising moves, though direct company news is sparse.
The outlook is cautious due to weak technical momentum and absent fundamental metrics. Risks include market volatility and lack of earnings visibility. Investment opportunity hinges on a rebound above resistance, but current sentiment and technicals suggest near-term pressure for stockholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →